INNV News and Press, InnovAge Holding Corp. From 02/09/22

InnovAge press release (NASDAQ:INNV): Q2 GAAP EPS of $0.01 misses by $0.03. Revenue of $175.35M (+11.5% Y/Y) beats by $1.41M. Center-level Contribution Margin of $41.4 million decreased 6.1% Y/Y. Adjusted EBITDA of $14.8M compared to $22.6M in the second quarter of fiscal 2021. For fur...

DENVER, Feb. 09, 2022 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (the “Company” or “InnovAge”) (Nasdaq: INNV), a market leading healthcare delivery platform for high-cost, dual-eligible seniors, announced financial results for its fiscal second quarter ended Dece...

DENVER, Jan. 27, 2022 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV) will release its 2022 fiscal second quarter financial results on Wednesday, February 9, 2022, after market close. In conjunction, the company will host a conference call to review the ...

RM LAW Announces Investigation of InnovAge Holding Corp. PR Newswire BERWYN, Pa. , Jan. 11, 2022 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of InnovAge Holding Corp. ("InnovAge" or the "Company") (NA...

DENVER, Jan. 03, 2022 (GLOBE NEWSWIRE) -- The Board of Directors of InnovAge Holding Corp. (the “Company” or “InnovAge”) (Nasdaq: INNV) accepted the resignation of longtime CEO and director Maureen Hewitt, effective January 1, 2022, who has decided after 15 years...

Gainers: Altamira Therapeutics (NASDAQ:CYTO) +21%, Regencell Bioscience (NASDAQ:RGC) +17%, BridgeBio Pharma BBIO +13%, ImmunityBio (NASDAQ:IBRX) +8%, BiondVax Pharmaceuticals BVXV +8%. Losers: Biofrontera (NASDAQ:BFRI) -21%, Microbot Medical (...

InnovAge (NASDAQ: INNV) is one company that will be very glad to see 2021 consigned to the history books. On Monday, the company's stock fell by 11%, on the back of two recommendation downgrades from prominent investment banks. The catalyst for the downgrades was InnovAge's disc...

Analyst comments factored heavily in Monday's midday action. InnovAge (NASDAQ:INNV) added to last week's losses following a downgrade, while Lucid Diagnostics (NASDAQ:LUCD) got a lift from a newly instated Buy rating. In other news, DiDi Global (NYSE:DIDI) suffered additional selling pressure...

Barclays analyst Sarah James downgraded InnovAge (NASDAQ:INNV) to Equal Weight from Overweight with a price target (PT) of $6.50, down from $22, after the company announced a sanction in its largest market, Colorado. Shares continue the downward trend, down 5% premarket after losing...

Stocks carried their recent optimism into the long holiday weekend, scoring modest gains on Thursday. The rally included Macau casino stocks, which rose on a promising signal from Chinese regulators. The news sparked gains in Melco Resorts & Entertainment (NASDAQ:MLCO), Las Vegas Sands (N...